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Proteolipid Protein Is Necessary
in Peripheral as Well as Central Myelin
James Y. Garbern,1,2 Franca Cambi,3 Xue-Ming Tang,3 Introduction
Anders A. F. Sima,1,4 Jean Michel Vallat,5
E. Peter Bosch,6 Richard Lewis,1 Michael Shy,1,2 Myelin is a multilamellar membrane structure surround-
Jasloveleen Sohi,1 George Kraft,7 Ke Lian Chen,8 ing axons in both the central and peripheral nervous
Indira Joshi,8 Debra G. B. Leonard,8 systems (CNS and PNS, respectively) that facilitates
William Johnson,9 Wendy Raskind,10 nerve conduction. In the CNS, myelin is synthesized by
Stephen R. Dlouhy,11 Victoria Pratt,11 oligodendrocytes, while in the PNS, myelin is produced
M. Edward Hodes,11 Thomas Bird,10,12 by Schwann cells. The myelin sheath consists of a series
and John Kamholz1,2 of concentrically wrapped cell membranes that are ex-
1Department of Neurology tensions of the oligodendrocyte or Schwann cell plasma
2Center for Molecular Medicine and Genetics membrane. During myelination, these membrane exten-
4Department of Pathology sions wrap repeatedly around individual axons, then
Wayne State University School of Medicine compact their apposed cytoplasmic and extracellular
Detroit, Michigan 48201 membrane surfaces to form the major dense and intra-
3Department of Neurology period lines of mature myelin.
Thomas Jefferson University School of Medicine The myelin membrane is composed mainly of lipid,
Philadelphia, Pennsylvania 19107 but also contains a number of structural proteins. In the
5Department of Neurology CNS, proteolipid protein (PLP), an integral membrane
University Hospital protein, is the major protein component of myelin, con-
F-87042 Limoges stituting z50% of myelin protein (Lees and Bizzozero,
France 1992). DM20, an alternative product of PLP splicing,
6Department of Neurology is a minor component of mature myelin, although it is
Mayo Clinic expressed at relatively higher amounts during embry-
Scottsdale, Arizona 85259 onic development (Schindler et al., 1990; Timsit et al.,
7Department of Physical Medicine and Rehabilitation 1992). In the PNS, however, P0, a member of the immu-
10Department of Medicine noglobulin supergene family encoded by MPZ (MIM
Division of Medical Genetics 159440), is the major myelin protein constituent (Wiggins
12Department of Neurology et al., 1975), while PLP constitutes ,1% of the total
University of Washington myelin protein (Lemke, 1992; Shy et al., unpublished
School of Medicine data). Both PLP/DM20 in the CNS and P0 in the PNS
Seattle, Washington 98195 are necessary for normal myelination, since mutations
8Molecular Diagnostics Laboratory of PLP and MPZ lead toabnormalities inmyelin structure
Department of Pathology and function (Hayasaka et al., 1993a, 1993b; Hodes et
University of Pennsylvania al., 1993; Griffiths et al., 1995; Martini et al., 1995a,
Philadelphia, Pennsylvania 19104 1995b;). Although PLP/DM20 is also expressed by
9Department of Neurology Schwann cells in the PNS, its role, if any, in peripheral
Robert Wood Johnson School of Medicine myelin is currently unknown (Puckett et al., 1987; Bizzo-
Piscataway, New Jersey 08854 zero et al., 1989; Agrawal and Agrawal, 1991; Gupta et
11Department of Medical and Molecular Genetics al., 1991; Pham-Dinh et al., 1991; Ikenaka et al., 1992;
Indiana University School of Medicine Kamholz et al., 1992). The precise function(s) of PLP/
Indianapolis, Indiana 46202±5251 DM20 is unknown, but roles in adhesion between adja-
cent myelin lamellae (Boison et al., 1995) and as an ion
channel have been proposed (Helynck et al., 1983).
Missense mutations of PLP cause a spectrum of CNSSummary
disease. The most devastating of these, Pelizaeus-Merz-
bacher disease (PMD, MIM 312080), is characterized byAlternative products of the proteolipid protein gene
nystagmus, delayed psychomotor development, spas-(PLP), proteolipid protein (PLP) and DM20, are ma-
ticity, ataxia, and optic atrophy (Seitelberger, 1970), andjor components of compact myelin in the central ner-
is accompanied by widespread CNS dysmyelinationvous system, but quantitatively minor constituents of
(Seitelberger, 1984, 1995; Koeppen et al., 1987; IyodaSchwann cells. A family with a null allele of PLP has
et al., 1988; Harding et al., 1995). The age of onset anda less severe CNS phenotype than those with other
rate of progression of PMD varies with the specificmuta-types of PLP mutations. Moreover, individuals with
tion. Missense mutations of PLP can also cause a lessPLP null mutations have a demyelinating peripheral
severe syndrome, X-linked complicated spastic para-neuropathy, not seen with other PLP mutations of
plegia (SPG) (Kobayashi et al., 1994; Saugier-Veber ethumans or animals. Direct analysis of normal periph-
al., 1994; Osaka et al., 1995; Cambi et al., 1996), which iseral nerve demonstrates that PLP is localized to com-
characterized by progressive lower extremity spasticitypact myelin. This and the clinical and pathologic ob-
servations of the PLP null phenotype indicate that and weakness, but without the widespread CNS dysmy-
elination and the clinical features typical of PMD.PLP/DM20 is necessary for proper myelin function
both in the central and peripheral nervous systems. Although PLP/DM20 is expressed by Schwann cells,
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missense mutations of PLP have not been associated Marks, 1990; Jasek et al., 1990; Wang et al., 1995). More-
over, the thickness of the corpus callosum was of normalwith peripheral nerve dysmyelination, by either electro-
dimensions for age, indicating that myelination had oc-physiologic or morphologic criteria (Hodes et al., 1993).
curred in this patient (Figure 2C). His evaluation forIn fact, previous reports of PMD distinguish this disorder
known causes of leukodystrophy, including adrenoleu-from other leukodystrophies, in part, by the absence of
kodystrophy, was negative.PNS abnormalities (Wilkus and Farrell, 1976). In addition,
Autopsy material from three individuals in this familya detailed clinical, electrophysiological, and histological
(V-5, death at age 47; V-6, death at age 45; and VI-6,examination of peripheral nerves in one patient with a
death at age 34) was evaluated and findings were similarduplication of PLP causing PMD found no abnormalities
for all three individuals. The gross pathology was note-in the PNS (Harding et al., 1995).
worthy for thinning of the corpus callosum, and grayIn this report, we demonstrate that a novel PLP muta-
discoloration of the cerebral and cerebellar whitematter.tion, a single base-pair deletion leading to the absence
Microscopic pathology demonstrated normal neuronalof PLP/DM20 expression, produces a disease similar
architecture of the cerebral and cerebellar cortex. Theto, but less severe, than typical PMD, and which in-
subcortical white matter showed severe diffuse myelincludes a progressive, demyelinating peripheral neurop-
loss, as assessed by histochemical staining, with betterathy. Electrophysiological evidence of demyelinating
preserved myelin in the subcortical U-fibers.peripheral neuropathy has been found in three affected
Since affected individuals had distal lower extremityindividuals in this kindred; pathological verification of
atrophy and distal proprioceptive loss, which suggestedboth central and peripheral demyelination has been
a peripheral neuropathy, peripheral nerve function offound in autopsymaterial from two others. The presence
four affected males was evaluated by nerve conductionof this demyelinating neuropathy clearly demonstrates
velocity (NCV) measurements, summarized in Tables 1that PLP/DM20 has an important function in the forma-
and 2. The distal motor latency (DML) is a measure oftion or maintenance of peripheral myelin in addition to
conduction velocity in distal nerve segments, which doits well known function in central myelin. Consistent with
not contribute to the determination of the nerve conduc-
this interpretation, we find by immunoelectron micros-
tion velocity. F waves are of particular value in assessing
copy that PLP is located in peripheral nerve compact
conduction in nerve segments proximal to those where
myelin, suggesting that PLP may play a structural role
conduction velocities are measured (Kimura, 1974;
in peripheral myelin as well. Young and Shahani, 1978; Panayiotopoulos and Chroni,
1996). Affected patients often had DML or F-wave pro-
Results longation that was out of proportion to the degree of
nerve conduction slowing across the major segment of
Identification of a Novel PLP Mutation Associated nerve. For example, at age 15, patient VI-7 had a median
with Both PMD and Demyelinating DML of 6.3 ms, whereas his conduction velocity was 42
Peripheral Neuropathy m/s, suggesting a greater degree of conduction slowing
A family with an X-linked leukodystrophy was identified across the wrist, which is characteristic of carpal tunnel
(see pedigree, Figure 1). Affected males demonstrated syndrome. This patient had a very abnormal ulnar
delay in both motor and cognitive development and had F-wave latency of 47 ms, which is prolonged beyond
optic pallor, limb spasticity, mild atrophy of the legs, expectation given his NCV values, and demonstrated
and decreased proprioception. Magnetic resonance im- the presence of proximal nerve demyelination. These
aging (MRI) of the brain of patient VI-7 at age 15, shown data are consistent with a demyelinating neuropathy
in Figure 2, shows increased T2 signal throughout the with multifocal conduction slowing. Mutations in the
cerebral white matter, consistent with a leukodystrophy. Cx32 coding region, and alteration in PMP22 copy num-
The severity of signal abnormalities was judged milder ber were excluded (not shown).
than those typically found in either connatal or classic The neuropathic phenotype demonstrated linkage to
DXS458 in Xq22 (lod 5 4.72 at u 5 0). A mutation in PLPPMD (Journel et al., 1987; Andre et al., 1990; Caro and
Figure 1. Pedigree of PMD Family
Individual V-30 has mild spastic paraparesis, urinary bladder dysfunction, and Babinski signs.
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in three affected males in this family (VI-6, V-5, and producing a stop codon two amino acids downstream
from the PLP initiation codon. Unambiguous assignmentV-6) was identified by single-stranded conformational
polymorphism analysis and further characterized by of which of the three G residues is deleted cannot be
made, and for simplicity, we will designate the deletedDNA sequencing. A deletion of one G residue in a triplet
of G residues, G-3, G-4, or G-5, numbered with respect G residue as G-4.
to the PLP open reading frame, was identified in both
individuals (see Figure 3). This deletion preserves a con- The G-4 PLP Deletion Does Not Alter Splicing
sensus splice donor sequence (Keller and Noon, 1984) Since the single base-pair deletion occurred in PLP im-
39 of the deleted G residue, and is predicted to result, mediately 59 of the splice donor site of intron 1, we
after splicing, in a frameshift of the PLP reading frame, analyzed the PLP mRNA structure directly to determine
whether normal splicing occurred at this point. This is
important, since normal splicing will produce a PLP
mRNA encoding only the three amino acids, divergent
from PLP after the initiation methionine, with the result
that no functional PLP or DM20 can be synthesized.
RNA was thus isolated from frozen brain tissue obtained
at autopsy from one of the affected males (V-5), and
subjected to reverse transcription±polymerase chain re-
action (RT±PCR) analysis, using a primer pair spanning
the intron 1 splice sites, and to Northern analysis. Two
bands of expected sizes, 630 and 590 nucleotides, re-
spectively, corresponding to the predicted alternatively
spliced products, PLP and DM20, were obtained from
both patient and control brain tissue in the RT±PCR
study (data not shown). DNA sequence analysis of the
RT±PCR product confirmed the presence of the G-4
deletion and the downstream stop codon (Figure 3).
Northern analysis (Figure 4) demonstrated that the PLP
mRNA from the affected individual was as long as that
from a normal patient. Had the G-4 deletion prevented
splicing, the mRNA length would be expected to be
significantly increased since the normal length of intron
1 is z7 kb. These data thus demonstrate that the G-4
deletion does not alter the PLP splicing pattern, and
should result in the inability to synthesize PLP/DM20.
The PLP G-4 Deletion Produces a Null PLP Allele
with Absence of PLP and DM20 Expression
To evaluate the effect of theG-4 deletion on PLP expres-
sion, we analyzed brain samples from patients V-5 and
V-6 for PLP expression by Western blotting and immu-
nohistochemistry. Northern analysis, shown in Figure 4,
demonstrates that PLP mRNA levels from the patient
samples are essentially the same as those from control
brain. In addition, the levels of myelin basic protein
(MBP) and cyclic nucleotide phosphohydrolase (CNP)
mRNAs, encoding two other myelin proteins, are also
the same in patient and control brain. Therefore, the
G-4 deletion has little effect on the accumulation of the
steady state levels of other myelin-specific mRNAs.
Western analysis of cerebral cortical tissue from indi-
viduals V-5 and V-6 demonstrated the complete ab-
sence of both PLP and the alternative PLP gene product,
DM20, both in unfractionated protein extracts and in a
purified myelin fraction (Figure 5A). MBP, however, is
readily detectable both in patient and control samples
(Figure 5B). In addition, the pattern of protein expression
in both whole brain extracts and in crude myelin is quali-
tatively very similar between affected individuals andFigure 2. Cerebral MRI Scan of Patient VI-7
the control samples, with the exception of PLP/DM20
(A and B) T2 weighted images. Note the increased T2 signal in the
(Figure 5A, lanes 1±6). These results show that the G-4cerebral white matter.
deletion produces a null PLP allele, which leads to the(C) T1 image demonstrating normal thickness of corpus callosum.
The scale bar 5 1 cm. absence of both PLP and DM20 expression, but with
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Table 2. Sensory Conduction Studies
Ulnar Median Sural
Latency Velocity Latency Velocity Latency Velocity
Patient (Age) Side Nl , 3.1 ms Nl . 54 m/s Nl , 3.5 ms Nl . 54 m/s Nl , 4.5 ms Nl . 41 m/s
VI-7 (5) 5.4
VI-7 (15) R Ð Ð Ð Ð NR NR
L 3.5 46 3.4 41 3.9 39
V-13 (27) R 4.2 4.2
V-13 (39) R Ð Ð
L 3.5 44 4.1 36 3.2 41
VI-5 (20) R 5.2 48
IV-1 (60) R 3.35 4.7
L 2.95 4.5
V-29 (36) 4.8 40
VI-13 (16) 3.3 47 3.4 60 4.0 42
RIII-5 (40) NR 4.1 Ð NR
RII-1 (67) 3.8 48 4.5 37 4.4 ±
Pro15Leu (20) L 1.6 50 2.7 46
PMD (28) L 2.9 47 3.2 44 2.6 54
Sensory conduction velocity measurements of individuals in Pelizaeus-Merzbacher families. The first six patients' values are from the family
with the PLP G-4 deletion. RIII-5 and RII-1 are individuals with deletion of PLP as described by Raskind et al. Pro15Leu, an affected male
from the family described by Trofatter et al. (1989); PMD, an individual with clinical classical Pelizaeus-Merzbacher disease; Nl, normal value;
NR, no response.
little effect on the expression of other major myelin pro- were incubated with PLP-antibody to demonstrate its
usefulness for detection of PLP in paraffin-embeddedteins, such as MBP.
To evaluate the spatial pattern of myelin protein ex- tissue. These observations are consistent with the West-
ern blotting results, and demonstrate that PLP, but notpression directly, we examined brain tissue from patient
V-5 by immunohistochemistry. As seen in Figures 6Aand MBP, expression is absent in CNS white matter. There-
fore, the area of demyelination most likely results from6D, there is extensive demyelination in the subcortical
white matter tracts as demonstrated by histochemical the absence of PLP.
staining for myelin. In the same area, however, there is
robust MBP staining (Figures 6B and 6E), but no immu- Individuals with the G-4 Deletion Have Morphological
Evidence of an Asymmetric, Demyelinatingnoreactive PLP (Figure 6C). At higher magnification,
MBP staining is associated with axons in the cerebellar Peripheral Neuropathy
Morphological evaluation of the peripheral nerves of thewhite matter (Figure 6E). Specimens of normal human
cerebellum (Figure 6F) and rat spinal cord (not shown) affected individuals in this kindred was performed on
Figure 3. Gene Structure of PLP
Inset shows the results of direct sequencing of RT±PCR products from a control brain (left) and an affected patient (right). Base G-4 is indicated
by an asterisk.
Neuron
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localized to compact myelin. To test this hypothesis,
we analyzed rat peripheral nerve by immunoelectron
microscopy with an antibody directed against the PLP-
specific portion of the protein. The results of this experi-
ment, shown in Figure 8, demonstrate that PLP is pres-
ent in adult rat nerve compact myelin.
Discussion
In this report, we describe a family with a novel PLP
mutation, a deletion of G-4 of the PLP coding region,
and demonstrate that this deletion produces a null PLP
allele, such that neither PLP, nor its alternatively spliced
product, DM20, is expressed. The absence of PLP/
DM20 expression produces a constellation of neurologi-
cal signs and symptoms similar to, but less severe thanFigure 4. Northern Analysis of Total RNA
those observed in most other patients with PMD. ThisSamples from: 1) control human patient, 2) patient V-5, and 3) 15-
day-old rat brain RNA, 10 mg each lane, probed for expression of: is associated with widespread CNS demyelination,
cyclic nucleotide phosphohydrolase (CNP), proteolipid protein gene which is evident on both cerebral MRI scans and neuro-
(PLP), myelin basic protein gene (MBP), and glyceraldehyde phos- pathological examination. In addition to its effect on
phate dehydrogenase (GADPH).
CNS myelin, the G-4 deletion causes a progressive de-
myelinating peripheral neuropathy, demonstrated by
both electrophysiological examination and neuropatho-
autopsy material available from individuals V-5 and V-6. logical analysis of autopsy specimens. These studies
Consistent with the presence of a demyelinating neu- demonstrate that PLP/DM20 is necessary in both pe-
ropathy, cross sections of the axillary (Figure 7A) and ripheral and central myelin in humans. We have also
sciatic (Figure 7B) nerve revealed marked loss of large shown by immunoelectron microscopy that PLP is local-
and small myelinated fibers and endoneurial fibrosis, ized to peripheral compact myelin. Taken together,
with occasional regenerating clusters. Preserved my- these observations suggest that PLP plays an important
elinated fibers often demonstrated splitting and degra- structural role in PNS myelin.
dation of the myelin sheath, which sometimes was ac-
companied by axonal atrophy and degeneration.
Comparison to Other Probable PLP Null FamiliesMacrophages were seen but were not present in large
Three additional families with null PLP mutations havenumbers. The endoneurial vessels showed thickened
been described previously. In two of these families, thebasement membranes.
entire PLP gene along with surrounding sequences wasTo demonstrate demyelination more clearly, samples
deleted (Raskind et al., 1991; Sugiyama et al., 1996). Afrom both axillary and sciatic nerve were assessed by
third family carries a G-to-A transition at the initiationteased fiber analysis. Scoring of teased fibers showed
codon of the PLP gene, leading to predicted absencehigh frequencies of fibers with segmental demyelination
of PLP/DM20 (Sistermans et al., 1996). The clinical phe-(Figure 7C) and paranodal demyelination (Figures 7D
notype in affected males in these three families, similarand 7E) in both the axillary and sciatic nerves (Table
to the family reported here, is distinctly less severe than3). Demyelination, particularly of the paranodal myelin,
that described in connatal and classical cases of PMD.could also be identified in longitudinal sections (Figure
The PNS was not formally evaluated in the two deletion7E). Paranodal and segmental demyelination were
families. Affected members of the family carrying a G-Aprominent in longitudinal sections. Axonal atrophy, indi-
transition in the initiation codon of PLP were found tocated by excessive myelin wrinkling (Table 3), and Wal-
have reduced conduction velocity on electrophysiologi-lerian degeneration were also observed. Taken together,
cal examination and had reduced numbers of myelin-these data are consistent with the physiology and mor-
ated fibers in the sural nerve. No molecular or biochemi-phology of a demyelinating peripheral neuropathy.
cal data confirming the absence of PLP/DM20 was
reported. We have recently evaluated the peripheralPLP Is Located in Compact Myelin in the
nerve function of an individual reported by Raskind andPeripheral Nerve
coworkers (1991), and have found asymmetrical slowingOur data from this family demonstrate that a null allele
of his NCVs, similar to that found for family membersof PLP can produce both CNS and PNS demyelination.
carrying thePLP G-4 deletion (Lewis, unpublished data).Since PLP is the major CNS myelin protein, the presence
These data further confirm the notion that PLP/DM20 isof CNS demyelination in these individuals is not unex-
necessary in both PNS and CNS myelin, and that thepected. In contrast, PLP/DM20 is expressed at much
absence of PLP/DM20 expression leads to myelin losslower levels in the PNS, and the role, if any, of PLP/
in both brain and peripheral nerve.DM20 in the peripheral nervous system has not been
determined. The presence of a demyelinating peripheral
neuropathy in this family demonstrates that PLP/DM20 Comparison to PLP Knockout Mice
Klugmann and coworkers (1997) recently reported thealso has an important function in PNS myelin. One
possible role for PLP/DM20 in PNS myelin is as a struc- analysis of a mouse line in which PLP had been inacti-
vated by homologous recombination. Animals that dotural myelin protein, where it would be expected to be
PLP Null Mutation
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not express PLP/DM20 appear to have normal CNS and after birth. If this is the case, humans lacking PLP would
form normal myelin during the first year of life, whenPNS myelin function since they do not have any signifi-
cant clinical disturbance of motor function. CNS com- human myelination peaks. Myelin would then break
down, leading to progressive neurological deterioration.pact myelin in the PLP knockout mouse has only subtle
ultrastructural abnormalities. These findings clearly dif- The clinical course of affected individuals carrying the
G-4 deletion is consistent with this hypothesis. Motorfer from those in patients with either a null PLP allele or
a PLP deletion, all of whom demonstrate clinical signs, and verbal skills are acquired during the first decade of
life but then are gradually lost. In addition, the thicknesssymptoms, and MRI evidence of CNS myelin loss. Af-
fected individuals carrying the G-4deletion, for example, and signal intensity of the corpus callosum of individual
VI-7 on MRI scan is normal at age 15, suggesting thathave clear evidence of abnormal myelin on MRI scan
(Figure 2), and analysis of autopsy material from individ- myelin was formed at this site. Other regions of the same
scan, however, clearly demonstrate abnormalities ofuals V-5 and V-6 demonstrates multiple areas devoid
of myelin staining, both in brain and peripheral nerve myelin (Figure 2). Finally, neuropathological evaluation
of brain specimens from individuals V-5 and V-6 shows(Figures 6 and 7). The individual reported by Raskind et
al. (1991) with a PLP deletion also has abnormal myelin areas of both relatively normal and abnormal myelination
(data not shown). Taken together, these data are consis-demonstrated by MRI scan.
The reasons for the differences between humans and tent with the notion that CNS myelin is formed during
development in individuals carrying the G-4 deletion,rodents that do not express PLP are not known. In their
recent paper describing the PLP knockout mouse, Klug- and subsequently breaks down, suggesting that PLP is
necessary for myelin stability, but not for myelin forma-mann and coworkers (1997) postulate that PLP is more
important for myelin stability in humans than in rodents, tion. While we cannot definitively explain the relative
lack of neurobehavioral abnormalities in the knockoutsuggesting that human myelin without PLP is inherently
unstable and eventually breaks down within a few years mice, possible reasons for the benign phenotype of the
Figure 5. Myelin Protein Expression in Pa-
tient and Control Samples
(A) Lanes 1±6: Coomassie brilliant blue
stained polyacrylamide SDS gel. Lanes 7±12:
Western blot stained for PLP/DM20. Antibody
to carboxy terminus of both PLP and DM20.
Patient V-5 samples were run in lanes 1, 4, 7,
and 10; patient V-6 samples were run in lanes
2, 5, 8, and 11. Control patient samples were
run in lanes 3, 6, 9, and 12. Crude myelin
extracts were run in lanes 1±3 and 7±9; total
brain homogenates were run in lanes 4±6 and
10±12. The positions of PLP and DM20 are
indicated.
(B) Western blot stained with antibody to bo-
vine MBP. Samples were total brain homoge-
nates from 1) patient V-5, 2) patient V-6, and
3) control brain. The location of the different
MBP forms is indicated by the bracket. Immu-
noreactivity of bands .21 kDa is probably
from golli-MBP.
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Figure 6. Myelin Staining and Myelin Protein Expression in Serial Sections of Cerebellum from Patient V-6
Sections were stained with ([A] and [D]) Luxol Fast Blue, or with antibody to MBP ([B] and [E]), or PLP (C).
(A±C) The same magnification; the scale bar 5 1 cm. Note the low level of myelin staining in the central white matter in (A).
(D and E) Serial sections at higher magnification of cerebellum from patient V-6 stained with Luxol Fast Blue (D) or for MBP (E) demonstrating
MBP staining along axons in the cerebellar white matter. The scale bar 5 40 mm.
(F) Section of cerebellum from a control patient stained for PLP. The scale bar 5 1 cm.
murine compared to the human null PLP condition in- matter of the PLP null patients are similar to those of
normal brains, in contrast to what has been observedclude compensatory mechanisms, perhaps by altered
expression of one or more myelin proteins; differences in the brains of other Pelizaeus-Merzbacher patients
(Koeppen et al., 1987) or in the brains of the severein absolute diameter of axons inmice relative tohumans;
and the effects of absolute or relative age. We speculate dysmyelinating murine PLP mutations, such as those of
jimpy mice (Skoff, 1995) or md rats (Nadon and Duncan,that the knockout mice of Nave and coworkers will have
evidence of demyelination in both the CNS and PNS if 1995). In these examples, mature oligodendrocyte num-
bers and levels of myelin gene and protein expressionthey are examined at a significantly later age.
are severely reduced. These observations and the find-
ing that PLP/DM20 is expressed during embryogenesisOligodendrocytes Develop Normally
in the Absence of PLP/DM20 in what appear to be the earliest oligodendrocytes or
their immediate precursors (Timsit et al., 1992, 1995; YuThe ability of PLP null patients to form myelin indicates
that oligodendrocytes developed normally in these indi- et al., 1994) have suggested that PLP/DM20 could be
important for the differentiation of oligodendrocytesviduals. Moreover, levels of myelin gene expression, as
demonstrated by those of myelin basic protein and MBP (Timsit et al., 1992). Our observations indicate that oligo-
dendrocytes can develop and survive in the completemRNA, and of PLP mRNA are comparable to those of
normal brain (Figures 4 and 5). Morphologically, the absence of PLP products.
The severe alleles of PLP likely act at the cellularnumbers of mature oligodendrocytes in the CNS white
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Figure 7. Peripheral Nerve Pathology
(A) Semithin section through axillary nerve of patient VI-6 shows loss of large and small myelinated fibers, endoneurial fibrosis, and occasional
regenerating clusters.
(B) Semithin sections through sciatic nerve of patient V-5 demonstrating thinly myelinated axons and reduced numbers of myelinated fibers;
endoneurial fibrosis. The scale bar ([A] and [B]) 5 20 mm.
(C and D) Teased fibers from sciatic nerve of patient VI-6 showing segmental demyelination (C) and paranodal demyelination (D).
(E) Semithin section of sciatic nerve demonstrating paranodal demyelination, marked by asterisks. The scale bar (C±E) 5 10 mm.
level in a dominant fashion to perturb maturation of 1994; Osaka et al., 1995). That complete lack of PLP/
DM20 expression results in a less severe PMD syndromeoligodendrocytes, perhaps by a toxic effect of the ab-
normally folded and unprocessed protein (Gow et al., demonstrates that normal DM20 processing is not the
only mechanism that can mitigate the effects of muta-1994; Nadon et al., 1994; Schneider et al., 1995). DM20
appears to be able to facilitate the processing of PLP tions affecting PLP.
(Sinoway et al., 1994). Mutations of PLP that spare DM20
or its processing generally have less severe phenotypes, PLP/DM20 Is Required for Normal
Peripheral Nerve Functionprobably due to DM20 substituting for PLP in myelin or
DM20 promoting the processing of the mutant PLP (Gow Most prior reports have not found evidence for periph-
eral neuropathy in patients with PMD. Hodeset al. (1993)and Lazzarini, 1996). In particular, mutations that affect
only PLP, but not DM20, are typically associated with reviewed their and others' clinical and genetic observa-
tions on patients with PMD and, except for the familythe less severe SPG phenotype (Saugier-Veber et al.,
Table 3. Teased Fiber Analysis
Axillary Nerve Sciatic Nerve
Number of teased fibers 94 93
% Abnormalities
Normal 18.1 33.3
Nodal±paranodal swelling 5.3 4.3
Paranodal demyelination 17.0 17.2
Segmental demyelination 37.2 34.4
Excessive myelin wrinkling 9.6 5.4
Intercalated internodes 1.1 3.2
Wallerian degeneration 11.7 2.2
Regeneration 0.0 0.0
Frequencies of specific pathologic changes in teased fibers from the axillary and sciatic nerves.
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Figure 8. Immunogold Electron Microscopic
Detection of (A) P0 and (B) PLP in Adult
Mouse Sciatic Nerve Myelin, Demonstrating
That PLP, as Well as P0, Localizes to Com-
pact Myelin
There were no discernible grains in Schwann
cell cytoplasm. (The scale bar 5 0.1 mm.)
reported in detail here, failed to find evidence of periph- that PLP is a quantitatively minor component of periph-
eral nerve (Lemke, 1992) and the report by Puckett eteral neuropathy in other patients where mutations have
been characterized. Furthermore, no morphological or al. (1987) that PLP in Schwann cells appears to be a
cytoplasmic, rather than membrane associated protein,physiological abnormalities of peripheral nerve have
been observed in jimpy mice or md rats, each of which raised the possibility that PLP did not serve an important
role in peripheral nerve, or at least one not directly re-has a PLP mutation that produces severe CNS hypomy-
elination and demyelination. In addition, we have found lated to myelin structure. Agrawal and Agrawal (1991)
on the other hand, using biochemical fractionation andno evidence of peripheral nerve dysfunction in a 20-
year-old man with a severe form of PMD caused by a immunoprecipitation, provided evidence that PLP is a
myelin protein in peripheral nerve. We provide the firstmissense mutation in codon 15 of the PLP coding region
(Trofatter et al., 1989, and unpublished data). ultrastructural evidence that PLP is present in normal
mammalian peripheral compact myelin, consistent withThese observations, combined with the knowledge
PLP Null Mutation
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Experimental Proceduresthe findings of Agrawal and Agrawal. The observations
of Puckett et al. are not necessarily in conflict with
Clinical Evaluationsthose reported here. It is possible that the cytoplasmic Patients VI-7 and V-13 were characterized electrophysiologically
staining observed by other investigators reflects a pool using a TECA Sapphire (TECA, Pleasantville, NY) instrument. Tem-
of protein that is not yet incorporated into cellular mem- perature was maintained at 31±328C. Patients RIII-5 and RII-1 (pa-
tients III-5 and II-1, respectively, described by Raskind et al., 1991)branes. Trapp et al. (1997) have shown that in the CNS,
were studied by G. H. K. Temperatures ranged from 30±368C exceptpremyelinating oligodendrocytes have PLP/DM20 stain-
for the tibial nerve in patient RIII-5 recorded at 258C. Surface elec-ing throughout the cell, whereas myelinating oligoden-
trodes were utilized in all studies, and sensory studies were anti-
drocytes express PLP only in the perinuclear cytoplasm dromic. Sensory velocities when determined were computed by
and myelin internodes. Furthermore, since other investi- dividing the distal onset latency into the distance between stimulat-
gators have used antisera that recognize both PLP and ing cathode and proximal recording electrode. Normals were based
on laboratory determined norms and published values (Gamstorp,DM20, it is possible that the relatively more abundant
1963; Baer and Johnson, 1965; Sunderland, 1968).DM20 (Pham-Dinh et al., 1991) is primarily being de-
Members of an Indiana kindred affected by a Pro15Leu mutationtected, and its signal overshadows that of PLP. The
of PLP, and which has been described in several prior reports (Ze-
antiserum used for immunolocalization in our study has man et al., 1964; Markand et al., 1982; Trofatter et al., 1989), were
been tested in a variety of settings, including Western examined clinically and electrophysiologically. The clinical syn-
drome in this family is extremely severe and would correspond toblotting and light microscopic immunocytochemistry
the connatal form of PMD, which includes seizures and growthand found to be both sensitive and specific (Asotra and
retardation. In addition, several patients ranging from 4±28 years ofMacklin, 1993; Duchala et al., 1995; Trapp et al., 1997).
age with clinically definite PMD (Boulloche and Aicardi, 1986), but
The intriguing phylogenetic analyses of P0, DM20, and without defined mutations, were studied. Although point and other
PLP by Yoshida and Colman (1996) demonstrate that small mutations in the PLP gene have been ruled out in these pa-
PLP/DM20 is present in PNS compact myelin of teleosts tients, duplications of the PLP gene have not been excluded in these
individuals. NCVs were normal in all cases (data not shown).and amphibians, providing an evolutionary precedent
for PLP in peripheral myelin. Lastly, although observed
Molecular Analysisin a mutant animal, PLP was found to reside in peripheral
DNA Analysisnerve myelin in homozygous P0 knockout mice, in which
Single-stranded conformational polymorphism analysis was per-
PLP overexpression may represent an attempt by the formed as described by Orita et al. (1989). The PLP exons were
Schwann cell to compensate for the absence of P0 amplified and sequenced as described by Pratt et al. (1993). The
amplification primers for exon 1 were 59-CTGGAGAGACCAGGATCC(Giese et al., 1992).
TTCC-39 and 59-TTCATGCTAAAGTTTTTGAAACTT-39. Single nucle-Missense PLP mutations are thought to act through
otide primer extension was done as previously described by Pratta dominant mechanism at the cellular level, suggesting
et al. (1993). The single nucleotide primer extension primer was
that disturbed protein±protein interactions involving mu- 59-GTCAGAGTCCCAAAGACATGG-39. a-32P dGTP was used to de-
tant PLP cause CNS demyelination (Gow et al., 1994; tect the normal allele; a-32P dTTP was used for the mutant allele;
Schneider et al., 1995; Gow and Lazzarini, 1996). Since and a-32P dATP was used as a negative control.
peripheral nerve function is normal in patients with mis-
CMT1A and CMTX Testingsense PLP mutations, the protein±protein interactions
To exclude the remote possibilities that the patients' peripheralinvolving mutant PLP in Schwann cells must differ from
nerve findings were related to coincidental CMT1A or CMTX, geno-
those in oligodendrocytes.This inference raises thepos- mic DNA from patient V-5 was analyzed for duplication of the 1.5
sibility that other mutations affecting PLP may result Mbp region associated with CMT1A by normalized Southern blot
in phenotypes that predominantly or even exclusively hybridization according to Chen et al. (1996), and complete se-
quencing of the coding exon of Cx32 (GJB1) was performed ac-affect the PNS.
cording to Bergoffen et al. (1993).Nerve conduction studies of individuals carrying the
G-4 deletion show multifocal, asymmetric slowing of
RNA Analysis
both motor and sensory conductions. This pattern of Slices of frontal lobes from individuals V-5 and V-6 were frozen
nerve conduction abnormality is distinct from that in within 8 hr after death, and stored at 2708C until used for molecular
the more common inherited demyelinating neuropathy, analysis. RNA was extracted from patient V-5, a control human
brain, and a 15-day-old rat brain, and analyzed by Northern analysisCharcot-Marie-Tooth disease type IA (CMT1A), in which
according to standard protocols (Sambrook et al., 1989). The mem-nerve conductions are uniformly slow (Kaku et al., 1993).
brane was hybridized successively with probes for human MBP,
Multifocal slowing of NCVs ischaracteristic of hereditary PLP, and glyceraldehyde phosphate dehydrogenase (GAPD).
neuropathy with liability to pressure palsies (HNPP, MIM RNA extracted from the brain of V-5 and from a normal brain
162500), which is due to deletion of one copy of the (Chomczynski and Sacchi, 1987) was reverse transcribed with AMV
reverse transcriptase (Promega) and oligo-dT and random primersPMP22 gene (Chance et al., 1993), and is often found
(Promega). A portion of the cDNA product was amplified with PLP-inacquired demyelinating neuropathies, such as chronic
specific 59 and 39 primers (271/247 and 1535/1559, respectively,inflammatory demyelinating peripheral neuropathy. An
according to Diehl et al., 1986). After a 2 min denaturation at 948C,
asymmetric and multifocal pattern of NCV slowing is the reactions were subjected to 35 cycles at 948C for 30 s, 558C for
consistent with the presence of regions of normal and 30 s, and 658C for 1 min, followed by a final extension at 658C for
6 min. Sequencing of the PCR product was carried out with anabnormal myelin. This pattern suggests that peripheral
internal primer (164/187, according to Diehl et al., 1986) or withmyelin is formed normally in individuals carrying a G-4
the same primers employed for amplification with the AmpliTaqdeletion, and subsequently breaks down, perhaps pref-
cycle sequencing kit (Perkin-Elmer). One hundred femptomoles of
erentially at compression points. PLP is thus also neces- the template, purified with a Qiaquick spin PCR purification kit (Qia-
sary for maintaining the integrity of the peripheral myelin gen), were annealed with 1.6 fmol of 32P-labeled primer and se-
quenced according to the manufacturer's specifications.sheath.
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Western Analysis followed by methylcellulose±uranyl acetate staining. Several other
investigators' PLP antisera were also used, including the carboxyFrontal lobe white matter (1 g) samples obtained from V-5 and V-6
and from a control brain were thawed and homogenized in 7 ml terminus±specific antiserum used for the Western analysis, but
failed to give any detectable signal. There was no staining when0.32 M sucrose (eight strokes each with A and B pestles of a Dounce
homogenizer). The homogenates were layered onto 8 ml 0.85 M primary antiserum was omitted.
sucrose and then subjected to centrifugation in a Beckman SW 28
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